Cv-andreas villunger

Curriculum vitae
Univ.-Prof. Dr. Andreas Villunger
Research Institution:
Medical University of Innsbruck, Biocenter, Division of Developmental Immunology, Innrain
80, 6020 Innsbruck, Austria
E-mail: [email protected]; http://www.apoptosis.at
Personal Data:
Date and place of birth: August 5th, 1967 in Innsbruck, Austria
Sex: Male; Soc.Sec.Nr.: 2369-050867; Citizenship: Austria
Research Interests:
Cell death signaling, Bcl-2 family, caspases, lymphocyte development and transformation
Publications:
105 publications in peer reviewed journals
1 invited book chapter, > 50 invited lectures
h-index: 39, Citations: > 4700
Education:

Matura, BRG Innsbruck (natural science branch), Austria Career History:

Undergraduate studies, University of Salzburg, Austria Master in Microbiology, University of Innsbruck, Austria (W. Doppler, Ph.D./MD, mentor). Ph.D. studies, Department of Internal Medicine, Hematology, University of Innsbruck, Austria (R. Greil MD, mentor) Postdoctoral Fellow, Medical Biochemistry Division, University of Innsbruck, Austria. Postdoctoral Fellow, WEHI, Melbourne, Australia Associate Professor at the Division of Experimental Pathophysiology, Medical University of Innsbruck, Austria. Venia docendi in Immunology, Medical University of Innsbruck, AUT Head of the Division for Dev. Immunology, Medical University of Innsbruck, Austria. § 99, Junior Professorship Primo loco as full professor (W3) for “Immunology” at the Technical University of Dresden (Germany) – declined. Appointment as §98 Univ.-Prof. and Director of the Division for Dev. Immunology, Biocenter, Medical University of Innsbruck, Austria. Personal Awards:
1999 Human Frontiers Science Program (HFSP) Long Term Fellowship
2001 Leukemia Research Foundation (LRF) Postdoctoral Fellowship
2003 “START” Prize of the Bundesministerium für Wissenschaft und Kultur
2004 “Otto Kraup” Prize for the best Austrian “venia” in 2004
2006 “Novartis-Prize” for Medical Research, provided by Novartis-Pharma, Vienna
Selected Invited Conference Lectures
Meeting of the European Immunology Societies, 6-9th September, 2006, Paris, FRA
Keystone Meeting on “Cell Death Pathways” 22nd-27th March, 2009, Whistler, CAN
21th EACR - Annual meeting, 26th-29th June 2010, Oslo, NOR
Keystone Meeting on „Beyond Cell Death“, 19th-24th March, 2012, Banff, CAN
Gordon Cell Death Conference, 15th-20th July, 2012, Lucca, ITA
Int. Symposium on Cell Death & Immunity, Dec. 11-12th, Cologne, GER
Reviewing Activities:
Reviewer for journal: Nature, Science, Immunity, Molecular Cell, Genes & Development.
Reviewer for grant agencies: Austrian National Bank (OeNB), Vienna, AUT;
Association for International Cancer Research (AICR), UK; German Cancer Aid, Bonn,
GER; The Italian Cancer Research Association (AIRC), Rome, ITA; The Irish National
Research Board (NRB), Dublin, IRL, Deutsche Forschungsgesellschaft (DFG),
Detusche Krebshilfe, Bonn, GER; Hong-Kong Research Council (HRC), Flanders
Research Council (FWO), Belgium; Austrian Academy of Science (ÖAW); Austrian
Cancer League, Science Foundation of Ireland (SFI), Fondation pour la Recherche
Médicale, Paris, FRA; Cancer Research UK, London, UK.
Career-related Activities
Editorial board member of “Cell Death & Differentiation” (NPG Publ. Group)
Editorial board member of “Apoptosis” (Springer)
Editorial board member of “Sci. Reports” (NPG Publ. Group),
Member of the Austrian Academy of Science “Junge Kurie”
Member of the Austrian Society of Immunology
Member of the European Cell Death Society
Major Current Research Grants:

1. Austrian Science Fund: # FWF-SFBF021, 2011-2013, € 500.000 “Tumor suppression in
response to DNA damage and oncogenic stress” 2. Austrian Science Fund: # FWF-DK, 2012-2014: Ph.D. program in „Molecular Cell Biology and Oncology (MCBO)“, € 270.000 3. Austrian Science Fund: stand alone project; 2011-2013: € 300.000 “BH3-only proteins 4. Deutsche Forschungsgemeinschaft: FOR 2036; 2014-2016: € 350.000 “New insights International Cooperation Partners:
Sharad Kumar, University of Adelaide, Australia
Samuel Sidi, The Tisch Cancer Institute, Mt. Sinai Medical School, New York
Roman Körner, MPI Martinsried, Germany
Andreas Strasser, WEHI, Melbourne, Australia
Ricky Johnstone, Peter Maccallum Cancer Center, Melbourne, Australia
10 most important scientific publications of the researcher’s entire career:
1. Manzl C, Peintner L, Krumschnabel G, Bock F, Labi V, Drach M, Newbold A, Johnstone R, Villunger A. PIDDosome-independent tumor suppression by
Caspase-2. Cell Death Differ. 2012. 19(10): 1722-32. doi: 10.1038/cdd.2012.54.
PMID: 22595758.
2. Frenzel A, Labi V, Chmelewskij W, Ploner C, Geley S, Fiegl H, Tzankov A, Villunger
A. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad.
Blood. 2010. 115(5):995-1005. doi: 10.1182/blood-2009-03-212670. PMID:
19965635.
3. Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J, Egle A, Villunger A. Apoptosis of leukocytes triggered by acute DNA damage promotes
lymphoma formation. Genes Dev. 2010. 24(15):1602-7. doi: 10.1101/gad.1940210.
PMID: 20679395.
4. Manzl C, Krumschnabel G, Bock F, Sohm B, Labi V, Baumgartner F, Logette E, Tschopp J, Villunger A. Caspase-2 activation in the absence of PIDDosome
formation. J Cell Biol. 2009. 185(2):291-303. doi: 10.1083/jcb.200811105. PMID:
19364921.
5. Labi V, Erlacher M, Kiessling S, Manzl C, Frenzel A, O'Reilly L, Strasser A, Villunger A. Loss of the BH3-only protein Bmf impairs B cell homeostasis and
accelerates gamma irradiation-induced thymic lymphoma development. J Exp Med.
2008. 205(3):641-55. doi: 10.1084/jem.20071658. PMID: 18299399.
6. Erlacher M, Labi V, Manzl C, Bock G, Tzankov A, Hacker G, Michalak E, Strasser A, Villunger A. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell
death during lymphocyte development, in apoptosis induction. J Exp Med. 2006.
203(13):2939-51. doi: 10.1084/jem.20061552. PMID: 17178918.
7. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, Adams JM, Strasser A, Villunger A. BH3-only proteins Puma and Bim are rate-limiting for
gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo.
Blood. 2005. 106(13):4131-8. doi: 10.1182/blood-2005-04-1595. PMID: 16118324.
8. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ,
Adams JM, Strasser A. p53- and drug-induced apoptotic responses mediated by
BH3-only proteins puma and noxa. Science. 2003. 302(5647):1036-8. doi:
10.1126/science.1090072. PMID: 14500851.
9. Villunger A, O'Reilly LA, Holler N, Adams J, Strasser A. Fas ligand, Bcl-2,
granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase:
Regulators of distinct cell death and survival pathways in granulocytes. J Exp Med.
2000. 192(5):647-58. PMID: 10974031.
10. Villunger A, Egle A, Marschitz I, Kos M, Bock G, Ludwig H, Geley S, Kofler R, Greil
R. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a
potential mechanism of tumor-induced suppression of immune surveillance. Blood.
1997. 90(1):12-20. PMID: 9207432.
Publications of the last 5 years (2013->2009):
Original Publications:
Death of p53-defective cells triggered by forced mitotic entry in the presence of DNA-
damage is not uniquely dependent on Caspase-2 or the PIDDosome
Manzl C, Fava LL, Krumschnabel G, Peintner L, Tanzer MC, Soratroi C, Bock FJ, Schuler
F, Luef B, Geley S and Villunger A; Cell Death Disease, accepted, 2013
Increased leukocyte survival and accelerated onset of lymphoma in absence of MCL-1
S159-phosphorylation.
Lindner S, Wissler M, Gruender A, Aumann K, Ottina E, Peintner L, Borner C, Charvet C,
Villunger A, Pahl H, Maurer C; Oncogene, accepted, 2013.
BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis. Wensveen
FM, Geest CR, Libregts SF, Derks IA, Ekert PG, Labi V, Villunger A, Nolte MA, Eldering E.
Apoptosis. 2013 Nov;18(11):1306-18. doi: 10.1007/s10495-013-0890-y.

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response.
Hannesdóttir L, Tymoszuk P, Parajuli N, Wasmer MH, Philipp S, Daschil N, Datta S, Koller
JB, Tripp CH, Stoitzner P, Müller-Holzner E, Wiegers GJ, Sexl V, Villunger A, Doppler W.
Eur J Immunol. 2013 Oct;43(10):2718-29

PARP-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice.
Farrés J, Martín-Caballero J, Martínez C, Lozano JJ, Llacuna L, Ampurdanés C, Ruiz-
Herguido C, Dantzer F, Schreiber V, Villunger A, Bigas A, Yélamos J. Blood. 2013 Jul
4;122(1):44-54.
AICAR induces Bax/Bak-dependent apoptosis through upregulation of the BH3-only
proteins Bim and Noxa in mouse embryonic fibroblasts.
González-Gironès DM, Moncunill-Massaguer C, Iglesias-Serret D, Cosialls AM, Pérez-
Perarnau A, Palmeri CM, Rubio-Patiño C, Villunger A, Pons G, Gil J. Apoptosis. 2013
Aug;18(8):1008-16.
Possible pitfalls investigating cell death responses in genetically engineered mouse models
and derived cell lines.
Manzl C, Baumgartner F, Peintner L, Schuler F, Villunger A. Methods. 2013 Feb 27.
doi:pii: S1046-2023(13)00031-5.
Loss of PIDD limits NF-κB activation and cytokine production but not cell survival or
transformation after DNA damage.
Bock FJ, Krumschnabel G, Manzl C, Peintner L, Tanzer MC, Hermann-Kleiter N, Baier G,
Llacuna L, Yelamos J, Villunger A. Cell Death Differ. 2013 Apr;20(4):546-57. doi:
10.1038/cdd.2012.152.
Labi V, Bertele D, Woess C, Tischner D, Bock F, Schwemmers S, Pahl H, Geley S, Kunze
D, Niemeyer C, Villunger A, Erlacher M. Haematopoietic Stem Cell Survival and
Transplantation Efficacy is Limited by the BH3—only Proteins Bim and Bmf
EMBO Mol Med. 2013 Jan;5(1):122-36. doi: 10.1002/emmm.201201235.

Necrosis-like death can engage multiple pro-apoptotic Bcl-2 protein family members.
Tischner D, Manzl C, Soratroi C, Villunger A, Krumschnabel G. Apoptosis. 2012
Nov;17(11):1197-209. doi: 10.1007/s10495-012-0756-8.

PINCH-1 promotes Bcl-2-dependent survival signalling and inhibits JNK-mediated apoptosis
in the primitive endoderm. Montanez E, Karaköse E, Tischner D, Villunger A, Fässler R. J
J Cell Sci. 2012 Nov 1;125(Pt 21):5233-40. doi: 10.1242/jcs.112029.

Baumgartner F, Woess C, Pedit V, Tzankov A, Labi V, Villunger A. Minor cell-death defects
but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf. Oncogene.
2012. doi: 10.1038/onc.2012.78. PMID: 22430207. [Epub ahead of print].
Bock FJ, Peintner L, Tanzer M, Manzl C, Villunger A. P53-induced protein with a death
domain (PIDD): master of puppets? Oncogene. 2012. doi: 10.1038/onc.2011.639. PMID:
22266869. [Epub ahead of print].
Brunner S, Herndler-Brandstetter D, Arnold CR, Wiegers GJ, Villunger A, Hackl M, Grillari
J, Moreno-Villanueva M, Burkle A, Grubeck-Loebenstein B. Upregulation of miR-24 is
associated with a decreased DNA damage response upon etoposide treatment in highly
differentiated CD8(+) T cells sensitizing them to apoptotic cell death. Aging Cell. 2012.
11(4):579-87. doi: 10.1111/j.1474-9726.2012.00819.x. PMID: 22435726.
Manzl C, Peintner L, Krumschnabel G, Bock F, Labi V, Drach M, Newbold A, Johnstone R,
Villunger A. PIDDosome-independent tumor suppression by Caspase-2. Cell Death Differ.
2012. 19(10): 1722-32. doi: 10.1038/cdd.2012.54. PMID: 22595758.
Ottina E, Grespi F, Tischner D, Soratroi C, Geley S, Ploner A, Reichardt HM, Villunger A*,
Herold MJ. Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in
leukocyte development in mice. Blood. 2012. 119(25):6032-42. doi: 10.1182/blood-2011-
12-399089. PMID: 22581448. *joint senior author
Ribe EM, Jean YY, Goldstein RL, Manzl C, Stefanis L, Villunger A, Troy CM. Neuronal
caspase 2 activity and function requires RAIDD, but not PIDD. Biochem J. 2012.
444(3):591-9. doi: 10.1042/bj20111588. PMID: 22515271.
Tischner D, Gaggl I, Peschel I, Kaufmann M, Tuzlak S, Drach M, Thuille N, Villunger A*,
Jan Wiegers G. Defective cell death signalling along the Bcl-2 regulated apoptosis pathway
compromises Treg cell development and limits their functionality in mice. J Autoimmun.
2012. 38(1):59-69. doi: 10.1016/j.jaut.2011.12.008. PMID: 22257939. *joint senior author
Tischner D, Wiegers GJ, Fiegl H, Drach M, Villunger A. Mutual antagonism of TGF-beta
and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells. Cell
Death Differ. 2012. 19(8):1277-87. doi: 10.1038/cdd.2012.7. PMID: 22322859.
Eitz Ferrer P, Potthoff S, Kirschnek S, Gasteiger G, Kastenmuller W, Ludwig H, Paschen
SA, Villunger A, Sutter G, Drexler I, Hacker G. Induction of Noxa-mediated apoptosis by
modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading
to IRF-3/IFN-beta-dependent induction of pro-apoptotic Noxa. PLoS Pathog. 2011.
7(6):e1002083. doi: 10.1371/journal.ppat.1002083. PMID: 21698224.
Grespi F, Ottina E, Yannoutsos N, Geley S, Villunger A. Generation and evaluation of an
IPTG-regulated version of Vav-gene promoter for mouse transgenesis. PLoS One. 2011.
6(3):e18051. doi: 10.1371/journal.pone.0018051. PMID: 21445314.
Hausmann M, Leucht K, Ploner C, Kiessling S, Villunger A, Becker H, Hofmann C, Falk W,
Krebs M, Kellermeier S, Fried M, Scholmerich J, Obermeier F, Rogler G. BCL-2 modifying
factor (BMF) is a central regulator of anoikis in human intestinal epithelial cells. J Biol
Chem. 2011. 286(30):26533-40. doi: 10.1074/jbc.M111.265322. PMID: 21673109.
Kirschnek S, Vier J, Gautam S, Frankenberg T, Rangelova S, Eitz-Ferrer P, Grespi F, Ottina
E, Villunger A, Hacker H, Hacker G. Molecular analysis of neutrophil spontaneous
apoptosis reveals a strong role for the pro-apoptotic BH3-only protein Noxa. Cell Death
Differ. 2011. 18(11):1805-14. doi: 10.1038/cdd.2011.69. PMID: 21660046.
Logette E, Schuepbach-Mallepell S, Eckert MJ, Leo XH, Jaccard B, Manzl C, Tardivel A,
Villunger A, Quadroni M, Gaide O, Tschopp J. PIDD orchestrates translesion DNA
synthesis in response to UV irradiation. Cell Death Differ. 2011. 18(6):1036-45. doi:
Melum E, Franke A, Schramm C, Weismuller TJ, Gotthardt DN, Offner FA, Juran BD,
Laerdahl JK, Labi V, Bjornsson E, Weersma RK, Henckaerts L, Teufel A, Rust C, Ellinghaus
E, Balschun T, Boberg KM, Ellinghaus D, Bergquist A, Sauer P, Ryu E, Hov JR,
Wedemeyer J, Lindkvist B, Wittig M, Porte RJ, Holm K, Gieger C, Wichmann HE, Stokkers
P, Ponsioen CY, Runz H, Stiehl A, Wijmenga C, Sterneck M, Vermeire S, Beuers U,
Villunger A, Schrumpf E, Lazaridis KN, Manns MP, Schreiber S, Karlsen TH. Genome-wide
association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility
loci. Nat Genet. 2011. 43(1):17-9. doi: 10.1038/ng.728. PMID: 21151127.
Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O, Moritz N, Hoelbl A,
Kovacic B, Freissmuth M, Muller M, Villunger A, Mullauer L, Schmatz AI, Streubel B,
Porpaczy E, Jager U, Stoiber D, Sexl V. The cooperating mutation or "second hit"
determines the immunologic visibility toward MYC-induced murine lymphomas. Blood.
2011. 118(17):4635-45. doi: 10.1182/blood-2010-10-313098. PMID: 21878673.
Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks KM, Ralli R, Scott CL,
Frenzel A, Villunger A, Johnstone RW. Deciphering the molecular events necessary for
synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and
the BH3 mimetic ABT-737. Cancer Res. 2011. 71(10):3603-15. doi: 10.1158/0008-
5472.can-10-3289. PMID: 21398407.
Frenzel A, Labi V, Chmelewskij W, Ploner C, Geley S, Fiegl H, Tzankov A, Villunger A.
Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. Blood.
2010. 115(5):995-1005. doi: 10.1182/blood-2009-03-212670. PMID: 19965635.
Grespi F, Soratroi C, Krumschnabel G, Sohm B, Ploner C, Geley S, Hengst L, Hacker G,
Villunger A. BH3-only protein Bmf mediates apoptosis upon inhibition of CAP-dependent
protein synthesis. Cell Death Differ. 2010. 17(11):1672-83.
Hagenbuchner J, Ausserlechner MJ, Porto V, David R, Meister B, Bodner M, Villunger A,
Geiger K, Obexer P. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-
apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity
independent of prosurvival MCL1 expression. J Biol Chem. 2010. 285(10):6904-12. doi:
10.1074/jbc.M109.038331. PMID: 20051518.
Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J, Egle A, Villunger A.
Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation.
Genes Dev. 2010. 24(15):1602-7. doi: 10.1101/gad.1940210. PMID: 20679395.
Parajuli N, Muller-Holzner E, Bock G, Werner ER, Villunger A, Doppler W. Infiltrating
CD11b+CD11c+ cells have the potential to mediate inducible nitric oxide synthase-
dependent cell death in mammary carcinomas of HER-2/neu transgenic mice. Int J Cancer.
2010. 126(4):896-908. doi: 10.1002/ijc.24805. PMID: 19653277.
Santidrian AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosialls AM, de Frias
M, Campas C, Gonzalez-Barca E, Alonso E, Labi V, Viollet B, Benito A, Pons G, Villunger
A, Gil J. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of
the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood. 2010.
116(16):3023-32. doi: 10.1182/blood-2010-05-283960. PMID: 20664053.
Huntington ND, Labi V, Cumano A, Vieira P, Strasser A, Villunger A, Di Santo JP, Alves
NL. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim sustains B lymphopoiesis
in the absence of IL-7. Int Immunol. 2009. 21(6):715-25. doi: 10.1093/intimm/dxp043.
PMID: 19454543.
Manzl C, Krumschnabel G, Bock F, Sohm B, Labi V, Baumgartner F, Logette E, Tschopp J,
Villunger A. Caspase-2 activation in the absence of PIDDosome formation. J Cell Biol.
2009. 185(2):291-303. doi: 10.1083/jcb.200811105. PMID: 19364921.
2. Reviews & Editorials:
Bim vanishes in the light of a mitotic Aurora, Fava LL, Haschka MD, Villunger A.
Cell Death Differ, in press (2013)
Bid-ding for mercy: twisted killer in action. Egle A, Asslaber D, Villunger A, Pinon-Hofbauer
J. Cell Death Differ. 2013 Jul;20(7):847-9.
Guarding effector T-cell survival: all for one, Mcl-1 for all? Ottina E, Pellegrini M, Villunger
A. Cell Death Differ. 2013 Aug;20(8):969-71.
Fava L, Bock F, Geley S, Villunger A. Caspase-2 at a Glance. J Cell Science, 2012 Dec
15;125(Pt 24):5911-5.
Tischner D, Villunger A. BCL-G aquitted of murder! Cell Death and Dis. 2012 Oct
11;3:e405. doi: 10.1038/cddis.2012.147.
Ottina E, Tischner D, Herold MJ, Villunger A. A1/Bfl-1 in leukocyte development and cell
death. Exp Cell Res. 2012. 318(11):1291-303. doi: 10.1016/j.yexcr.2012.01.021. PMID:
22342458.
Baumgartner F, Villunger A. Apoptosis: a barrier against cancer no more? Hepatology.
2011. 54(4):1121-4. doi: 10.1002/hep.24637. PMID: 21898490.
Bock FJ, Villunger A. GSK3 TIPping off p53 to unleash PUMA. Mol Cell. 2011. 42(5):555-
6. doi: 10.1016/j.molcel.2011.05.022. PMID: 21658596.
Villunger A, Labi V, Bouillet P, Adams J, Strasser A. Can the analysis of BH3-only protein
knockout mice clarify the issue of 'direct versus indirect' activation of Bax and Bak? Cell
Death Differ. 2011. 18(10):1545-6. doi: 10.1038/cdd.2011.100. PMID: 21909118.
Wiegers GJ, Kaufmann M, Tischner D, Villunger A. Shaping the T-cell repertoire: a matter
of life and death. Immunol Cell Biol. 2011. 89(1):33-9. doi: 10.1038/icb.2010.127. PMID:
21060321.
Labi V, Villunger A. PUMA-mediated tumor suppression: A tale of two stories. Cell Cycle.
2010. 9(21):4269-75. PMID: 20980816.
Tischner D, Woess C, Ottina E, Villunger A. Bcl-2-regulated cell death signalling in the
prevention of autoimmunity. Cell Death Dis. 2010. 1:e48. doi: 10.1038/cddis.2010.27.
PMID: 21364654.
Villunger A. Only the strong survive. Immunity. 2010. 32(6):729-31. doi:
10.1016/j.immuni.2010.06.010. PMID: 20620937.
Frenzel A, Grespi F, Chmelewskij W, Villunger A. Bcl2 family proteins in carcinogenesis
and the treatment of cancer. Apoptosis. 2009. 14(4):584-96. doi: 10.1007/s10495-008-
0300-z. PMID: 19156528.
Krumschnabel G, Manzl C, Villunger A. Caspase-2: killer, savior and safeguard--emerging
versatile roles for an ill-defined caspase. Oncogene. 2009. 28(35):3093-6. doi:
10.1038/onc.2009.173. PMID: 19581929.

Source: http://www.apoptosis.at/members/CV-Andreas%20Villunger.pdf